vs
GLAUKOS Corp（GKOS）与GLOBUS MEDICAL INC（GMED）财务数据对比。点击上方公司名可切换其他公司
GLOBUS MEDICAL INC的季度营收约是GLAUKOS Corp的5.8倍（$826.4M vs $143.1M）。GLOBUS MEDICAL INC净利率更高（17.0% vs -93.4%，领先110.4%）。GLAUKOS Corp同比增速更快（35.7% vs 25.7%）。GLOBUS MEDICAL INC自由现金流更多（$202.4M vs $3.9M）。过去两年GLAUKOS Corp的营收复合增速更高（29.3% vs 16.7%）
Glaukos Corp是一家专注于眼科领域的医疗科技企业，开发并商业化用于治疗青光眼、角膜疾病等眼部病症的微创手术器械、处方药物及消费级产品，主要市场覆盖北美、欧洲及亚太地区，为全球医院、眼科诊所及患者提供服务。
Globus Medical是总部位于美国宾夕法尼亚州奥杜邦的上市骨科医疗器械企业，专注于相关产品的设计、研发与商业化，助力外科医生为肌肉骨骼系统疾病患者提供治疗方案，促进患者康复。
GKOS vs GMED — 直观对比
营收规模更大
GMED
是对方的5.8倍
$143.1M
营收增速更快
GKOS
高出9.9%
25.7%
净利率更高
GMED
高出110.4%
-93.4%
自由现金流更多
GMED
多$198.5M
$3.9M
两年增速更快
GKOS
近两年复合增速
16.7%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $143.1M | $826.4M |
| 净利润 | $-133.7M | $140.6M |
| 毛利率 | -1.1% | 68.4% |
| 营业利润率 | -97.7% | 20.5% |
| 净利率 | -93.4% | 17.0% |
| 营收同比 | 35.7% | 25.7% |
| 净利润同比 | -298.0% | 430.4% |
| 每股收益（稀释后） | $-2.34 | $1.01 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收GKOSGMED
| Q4 25 | $143.1M | $826.4M | ||
| Q3 25 | $133.5M | $769.0M | ||
| Q2 25 | $124.1M | $745.3M | ||
| Q1 25 | $106.7M | $598.1M | ||
| Q4 24 | $105.5M | $657.3M | ||
| Q3 24 | $96.7M | $625.7M | ||
| Q2 24 | $95.7M | $629.7M | ||
| Q1 24 | $85.6M | $606.7M |
净利润GKOSGMED
| Q4 25 | $-133.7M | $140.6M | ||
| Q3 25 | $-16.2M | $119.0M | ||
| Q2 25 | $-19.7M | $202.8M | ||
| Q1 25 | $-18.1M | $75.5M | ||
| Q4 24 | $-33.6M | $26.5M | ||
| Q3 24 | $-21.4M | $51.8M | ||
| Q2 24 | $-50.5M | $31.8M | ||
| Q1 24 | $-40.8M | $-7.1M |
毛利率GKOSGMED
| Q4 25 | -1.1% | 68.4% | ||
| Q3 25 | 78.4% | 67.2% | ||
| Q2 25 | 78.3% | 66.6% | ||
| Q1 25 | 77.2% | 67.3% | ||
| Q4 24 | 72.9% | 59.9% | ||
| Q3 24 | 76.6% | 56.8% | ||
| Q2 24 | 76.4% | 58.7% | ||
| Q1 24 | 76.3% | 60.2% |
营业利润率GKOSGMED
| Q4 25 | -97.7% | 20.5% | ||
| Q3 25 | -12.3% | 17.9% | ||
| Q2 25 | -18.3% | 10.2% | ||
| Q1 25 | -19.4% | 16.2% | ||
| Q4 24 | -27.2% | 9.2% | ||
| Q3 24 | -25.5% | 7.7% | ||
| Q2 24 | -31.3% | 7.9% | ||
| Q1 24 | -45.6% | 1.3% |
净利率GKOSGMED
| Q4 25 | -93.4% | 17.0% | ||
| Q3 25 | -12.2% | 15.5% | ||
| Q2 25 | -15.8% | 27.2% | ||
| Q1 25 | -17.0% | 12.6% | ||
| Q4 24 | -31.8% | 4.0% | ||
| Q3 24 | -22.1% | 8.3% | ||
| Q2 24 | -52.8% | 5.0% | ||
| Q1 24 | -47.7% | -1.2% |
每股收益（稀释后）GKOSGMED
| Q4 25 | $-2.34 | $1.01 | ||
| Q3 25 | $-0.28 | $0.88 | ||
| Q2 25 | $-0.34 | $1.49 | ||
| Q1 25 | $-0.32 | $0.54 | ||
| Q4 24 | $-0.56 | $0.19 | ||
| Q3 24 | $-0.39 | $0.38 | ||
| Q2 24 | $-1.00 | $0.23 | ||
| Q1 24 | $-0.82 | $-0.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $90.8M | $557.2M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $656.2M | $4.6B |
| 总资产 | $893.5M | $5.3B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资GKOSGMED
| Q4 25 | $90.8M | $557.2M | ||
| Q3 25 | $98.2M | $18.8M | ||
| Q2 25 | $100.8M | — | ||
| Q1 25 | $114.3M | — | ||
| Q4 24 | $169.6M | $890.1M | ||
| Q3 24 | $100.1M | $71.9M | ||
| Q2 24 | $68.1M | $82.5M | ||
| Q1 24 | $42.5M | $80.4M |
股东权益GKOSGMED
| Q4 25 | $656.2M | $4.6B | ||
| Q3 25 | $769.5M | $4.4B | ||
| Q2 25 | $765.1M | $4.3B | ||
| Q1 25 | $764.0M | $4.1B | ||
| Q4 24 | $766.9M | $4.2B | ||
| Q3 24 | $668.5M | $4.1B | ||
| Q2 24 | $665.2M | $4.0B | ||
| Q1 24 | $450.7M | $3.9B |
总资产GKOSGMED
| Q4 25 | $893.5M | $5.3B | ||
| Q3 25 | $999.4M | $5.1B | ||
| Q2 25 | $987.0M | $5.0B | ||
| Q1 25 | $966.2M | $4.7B | ||
| Q4 24 | $974.8M | $5.3B | ||
| Q3 24 | $926.5M | $5.1B | ||
| Q2 24 | $919.7M | $5.0B | ||
| Q1 24 | $933.3M | $4.9B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $6.8M | $248.6M |
| 自由现金流经营现金流 - 资本支出 | $3.9M | $202.4M |
| 自由现金流率自由现金流/营收 | 2.7% | 24.5% |
| 资本支出强度资本支出/营收 | 2.0% | 5.6% |
| 现金转化率经营现金流/净利润 | — | 1.77× |
| 过去12个月自由现金流最近4个季度 | $-22.5M | $588.8M |
8季度趋势，按日历期对齐
经营现金流GKOSGMED
| Q4 25 | $6.8M | $248.6M | ||
| Q3 25 | $-10.1M | $249.7M | ||
| Q2 25 | $7.0M | $77.9M | ||
| Q1 25 | $-18.5M | $177.3M | ||
| Q4 24 | $507.0K | $210.3M | ||
| Q3 24 | $-9.6M | $203.7M | ||
| Q2 24 | $-18.4M | $54.3M | ||
| Q1 24 | $-33.9M | $52.4M |
自由现金流GKOSGMED
| Q4 25 | $3.9M | $202.4M | ||
| Q3 25 | $-11.7M | $213.9M | ||
| Q2 25 | $5.8M | $31.3M | ||
| Q1 25 | $-20.5M | $141.2M | ||
| Q4 24 | $-1.2M | $193.2M | ||
| Q3 24 | $-11.0M | $161.7M | ||
| Q2 24 | $-20.5M | $26.5M | ||
| Q1 24 | $-34.8M | $23.8M |
自由现金流率GKOSGMED
| Q4 25 | 2.7% | 24.5% | ||
| Q3 25 | -8.8% | 27.8% | ||
| Q2 25 | 4.7% | 4.2% | ||
| Q1 25 | -19.2% | 23.6% | ||
| Q4 24 | -1.2% | 29.4% | ||
| Q3 24 | -11.4% | 25.8% | ||
| Q2 24 | -21.4% | 4.2% | ||
| Q1 24 | -40.7% | 3.9% |
资本支出强度GKOSGMED
| Q4 25 | 2.0% | 5.6% | ||
| Q3 25 | 1.2% | 4.7% | ||
| Q2 25 | 0.9% | 6.2% | ||
| Q1 25 | 1.8% | 6.0% | ||
| Q4 24 | 1.6% | 2.6% | ||
| Q3 24 | 1.5% | 6.7% | ||
| Q2 24 | 2.2% | 4.4% | ||
| Q1 24 | 1.1% | 4.7% |
现金转化率GKOSGMED
| Q4 25 | — | 1.77× | ||
| Q3 25 | — | 2.10× | ||
| Q2 25 | — | 0.38× | ||
| Q1 25 | — | 2.35× | ||
| Q4 24 | — | 7.94× | ||
| Q3 24 | — | 3.93× | ||
| Q2 24 | — | 1.71× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
GKOS
| Glaucoma | $86.4M | 60% |
| Other | $35.1M | 25% |
| Corneal Health | $21.6M | 15% |
GMED
| Other | $391.8M | 47% |
| Nevro Merger Agreement | $293.6M | 36% |
| Enabling Technologies | $141.0M | 17% |
